6 results match your criteria: "Centre Pilote de Suivi Biologique des Traitements par Anticorps (CePiBAc)[Affiliation]"
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases.
Exp Hematol Oncol
April 2024
Université Paris Cité, INSERM, UMR_S942 MASCOT, Paris, F-75006, France.
Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after intravenous injection and the significant efflux of drugs, including monoclocal antibodies, after administration into the cerebrospinal fluid. We hypothesized that this efflux was linked to the presence of a FcRn receptor in the blood-brain barrier.
View Article and Find Full Text PDFEfficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
J Intern Med
December 2023
Centre Rendu-Osler, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Université de Versailles SQY, Boulogne, France.
Article Synopsis
- Bevacizumab, a monoclonal antibody, is used to treat hereditary hemorrhagic telangiectasia (HHT), but this is the first randomized trial investigating its effectiveness.
- In a double-blind study involving 24 patients, those treated with bevacizumab showed a greater decrease in blood transfusions compared to the placebo group, with significant improvements in hemoglobin levels over six months.
- Despite some positive results, the trial was underpowered, meaning more research is needed to confirm that bevacizumab helps reduce the need for blood transfusions in HHT patients, especially in those exposed to higher doses.
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
Clin Pharmacokinet
September 2023
EA4245 Transplantation, Immunologie, Inflammation (T2i), Tours University, Tours, France.
Background And Objective: Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The influence of target-antigen on cetuximab pharmacokinetics has never been investigated using target-mediated drug disposition (TMDD) modelling. This study aimed to investigate the relationship between cetuximab concentrations, target kinetics and progression-free survival (PFS).
View Article and Find Full Text PDFPanitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells.
Biomark Med
June 2021
Université de Tours, EA 7501, GICC, France.
Resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (CRC) is frequent and prognostic biomarkers are lacking. MicroRNAs (miR) are good candidates in this context. We aimed to characterize cetuximab and panitumumab exposure influence on miR expression in colorectal cancer cells to identify those regulating the EGFR pathway and implicated in resistance to treatment.
View Article and Find Full Text PDFA robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations.
Bioanalysis
April 2021
CHRU de Tours, Plateforme Recherche, Centre Pilote de Suivi Biologique des Traitements par Anticorps (CePiBAc), Tours, France.
Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship. An ELISA was developed and validated according to the international guidelines for ligand-binding assays.
View Article and Find Full Text PDFTherapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.
Vaccines (Basel)
February 2021
INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032 Tours, France.
Respiratorytract infections (RTIs) are frequent and life-threatening diseases, accounting for several millions of deaths worldwide. RTIs implicate microorganisms, including viruses (influenza virus, coronavirus, respiratory syncytial virus (RSV)), bacteria (, , and ) and fungi ( spp., spp.
View Article and Find Full Text PDF